

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Evaluation of the effect of high protein nutritional support in comparison to nutritional support with regular protein intake in intensive care unit patients: a double-blind randomized clinical trial

Protocol summary

Study aim

Evaluation of the effect of high-protein nutritional support compared to conventional-protein nutritional support in critically ill patients admitted to the intensive care unit

Design

This parallel, randomized, double-blind clinical trial was conducted on 60 ICU patients at Imam Reza Hospital, Mashhad, Iran. Participants were randomly allocated (1:1) using stratified block randomization (by age and sex; block size of 4). An independent statistician generated the allocation sequence using a random number table, and assignments were concealed in opaque, sequentially numbered envelopes, opened only after confirming eligibility.

Settings and conduct

Eligible ICU patients at Imam Reza Hospital will be enrolled after specialist assessment. Weight, height (via ulna length), and MUAC will be measured. Demographic, clinical, and laboratory data will be recorded. High- and conventional-protein BTF formulas (2.2 vs. 1.0 g/kg/day) will be prepared in identical containers (Formula A/B) and will be visually indistinguishable. Patients will receive gavage feeding every 3 hours, 7 times daily, for 12 days.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age 18–80 years, ICU admission with ≥ 72 hours of mechanical ventilation, legal consent or judicial approval, Enteral feeding possible within 48 hours, No participation in other interventional studies. Exclusion criteria: Pregnancy or lactation, Exclusive need for parenteral nutrition, History of liver cirrhosis or end-stage renal disease, Inability to tolerate enteral feeding, Intervention duration < 4 days, Frequent transfusions or physician-determined ineligibility.

Intervention groups

Intervention: 2.2 g/kg of Karen's Iso Whey protein per day
Control: 1 g/kg of Karen's Iso Whey protein per day

Main outcome variables

60 days mortality

General information

Reason for update

Correction of trial information based on the latest protocol version

Acronym

IRCT registration information

IRCT registration number: **IRCT20180619040151N4**

Registration date: **2019-11-07, 1398/08/16**

Registration timing: **registered_while_recruiting**

Last update: **2025-07-15, 1404/04/24**

Update count: **1**

Registration date

2019-11-07, 1398/08/16

Registrant information

Name

Abdolreza Norouzy

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 3800 2382

Email address

norouzya@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-10-11, 1398/07/19

Expected recruitment end date

2020-07-09, 1399/04/19

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Evaluation of the effect of high protein nutritional support in comparison to nutritional support with regular protein intake in intensive care unit patients: a double-blind randomized clinical trial

Public title
Determination of the effect of high protein nutritional support in comparison to nutritional support with common protein in intensive care unit patients

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
 18-80 years old Patients who have been ventilated for at least the first 72 hours of admission Completion of informed consent form in the first stage of legal guardianship in case of failure in this field to the judge. Ability to enteral feed in the first 24 to 48 hours of admission. Lack of participation in any other interventional research project. ICU admission
Exclusion criteria:
 Pregnant or lactation Patients require only parenteral nutrition History of diseases such as hepatocirrhosis and End-stage renal disease. inability to tolerate EN receipt of the study intervention for fewer than four days frequent need for blood transfusions; or physician discretion deeming the patient unsuitable for participation.

Age
From **18 years** old to **80 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Outcome assessor

Sample size
Target sample size: **60**

Randomization (investigator's opinion)
Randomized

Randomization description
After selecting 60 patients based on inclusion criteria, they will be divided into two groups of intervention or control through stratified block randomization by using the numbered, sealed and stapled envelopes.

Blinding (investigator's opinion)
Double blinded

Blinding description
In the present study, both patients and outcome assessors will be blinded throughout the study.

Placebo
Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mashhad university of Medical Sciences

Street address

Mashhad University of Medical Sciences, Mashhad, Park Square.

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Approval date

2018-12-11, 1397/09/20

Ethics committee reference number

IR.MUMS.MEDICAL.REC.1397.543

Health conditions studied

1

Description of health condition studied

Critical ill patients

ICD-10 code

Z00.01

ICD-10 code description

Encounter for general adult medical examination with abnormal findings

Primary outcomes

1

Description

mortality

Timepoint

mortality in the intensive care unit, days 28 and 60 after intaking protein

Method of measurement

If the patient is discharged from the intensive care unit, the patient will be contacted by telephone.

Secondary outcomes

1

Description

Nutrition Risk in the Critically Ill (NUTRIC) Score

Timepoint

Before intervention
Method of measurement
Nutrition Risk in the Critically Ill (NUTRIC) Score

2

Description
Acute Physiology and Chronic Health Evaluation (APACHE II) score changes
Timepoint
Before intervention
Method of measurement
Acute Physiology and Chronic Health Evaluation (APACHE II) score

3

Description
Sequential Organ Failure Assessment (SOFA) score
Timepoint
Before intervention, day 3, 5, 7, 9 and 11
Method of measurement
Sequential Organ Failure Assessment (SOFA) Score

4

Description
SARC-F Screen for Sarcopenia changes
Timepoint
Before intervention
Method of measurement
SARC-F Score

5

Description
Clinical Frailty Scale changes
Timepoint
Before intervention
Method of measurement
Clinical Frailty Scale score

Intervention groups

1

Description
The intervention group received 2.2 g/kg/day of Karen's Iso Whey protein via gavage feeding for 12 days. Surplus protein was primarily provided through enteral nutrition (BTF), with parenteral amino acids used only if enteral intake was insufficient.
Category
N/A

2

Description
Control group: 1 g / kg of Karen's Iso Whey protein per day by gavage feeding method in 12 days. (This amount of surplus protein will be given with BTF is given to patients.)
Category

Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Emamreza hospital
Full name of responsible person
Alireza Sedaghat
Street address
Ebne Sina Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
99191-91778
Phone
+98 51 3800 2429
Email
SedaghatAR@mums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Mohsen Tafaghodi
Street address
Mashhad University of Medical Sciences, 18
Daneshgah Ave. Daneshgah Ave
City
Mashhad
Province
South Khorasan
Postal code
9196773117
Phone
+98 51 1882 3255
Fax
+98 51 1882 3251
Email
tafaghodim@mums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mashhad University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Abdolreza Norouzy

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Nutrition

Street address

Azadi-square

City

Mashhad

Province

Razavi Khorasan

Postal code

99191-91778

Phone

+98 51 3800 2382

Fax

+98 51 3800 2421

Email

norouzya@mums.ac.ir

Phone

+98 51 3800 2382

Fax

+98 51 3800 2421

Email

norouzya@mums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohaddeseh Badpeyma

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

Bahonar Blvd

City

Mashhad

Province

Razavi Khorasan

Postal code

91779-48988

Phone

+98 51 3882 8299

Email

Badpimamh961@mums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Abdolreza Norouzy

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Nutrition

Street address

Azadi-square

City

Mashhad

Province

Razavi Khorasan

Postal code

99191-91778

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available